Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-16. (Cancelled)

17. (Currently amended) A method for preparing a composite product comprising a step in which an active substance in powder form undergoes co-grinding with a carrier, said carrier being ~~comprising~~ N-vinyl-2-pyrrolidone/vinyl acetate copolymer in powder form, wherein the co-grinding step is carried out in the grinding chamber of a grinding mill for times between 0.1 to 48 hours.

18. (Cancelled)

19. (Previously presented) The method according to claim 17, in which the co-grinding step takes place in dry conditions.

20. (Previously presented) The method according to claim 17, in which the active substance is chosen among non steroidal anti-inflammatory agents.

21. (Previously presented) The method according to claim 17, in which the active substance is chosen among anti-hypertensives.

22. (Previously presented) The method according to claim 17, in which the active substance is chosen among hepato-biliary agents.

23-24. (Cancelled)

25. (Previously presented) The method according to claim 17, in which the active substance is chosen among: anti-inflammatory agents, analgesics, relaxants, anti-microbic agents, antiseptics, acid pump inhibitors, H_2 antagonists, anti-emetics and anti-nausea, biliary acids, oral hypoglycemizers, diuretics, anti-hypertensives, sulfonamides, ace-inhibitors, hypolipemizers, anti-mycotic agents, antihistamines, hormones, quinolone derivates, antibacterial agents, beta-lactame and fluoroquinolone antibiotics, antiviral agents, anti-neoplastic agents, immuno-modulators and immuno-suppressors, anti-gout agents,

anesthetics, analgesics, antipyretics, $5HT_1$ agonists, anti-Parkinson agents, anti- psychotic agents, tranquillizers, antidepressants, anti-parasitic agents, non-cortisone anti-allergic agents, anti-asthmatic agents, anti-glaucoma agents, inhibitors of carbonic anhydrase or beta-blockers.

26. (Previously presented) The method according to claim 25, in which the active substance is chosen among: paracetamol, nifedipine, piroxicam, ibuprofen, sulindac, diclofenac, alclofenac, ketorolac, indomethacine, naproxen, fenoprofen, flurbiprofen, ketoprofen, cimetidine, ranitidine, mesalazine, ursodeoxycholic acid, mefenamic acid, sinvastatin, megestrol acetate, lorazepam, diazepam, cyclosporin, ubiquinone, tolbutamide, ketanserine, furosemide, nicergoline, losartan, econazole, miconazole, taxol, progesterone, prednisolone, beclometasone, nalidixic acid, finasteride, ciprofloxacine, ofloxacine, lomefloxacine, methotrexate, etoposide, daunorubicine, tamoxifen, allopurinol, clodronic acid, sumatriptan, carbamazepine, clorpromazine, clozapine, sulpiride, buspirone, fluoxetine, citalopram, caffeine, metronidazole, acetazolamide.

27. (Previously presented) The method according to claim 17, in which the active substance and N-vinyl-2-pyrrolidone/vinyl acetate copolymer are present in a weight ratio between 1:200 and 10:1.

28. (Previously presented) The method according to claim 27, in which the active substance and N- vinyl-2-pyrrolidone/vinyl acetate copolymer are present in a weight ratio between 1:100 and 5:1.

29. (Previously presented) The method according to claim 17, in which the active substance and N-vinyl-2-pyrrotidone/vinyl acetate copolymer are premixed in powder mixer.

30. (Currently amended) The method according to claim 17, in which the mixture comprising the active substance and N-vinyl-2-pyrrolidone/vinyl acetate copolymer is introduced into the grinding chamber of the grinding mill without premixing.

31. (Previously presented) The method according to claim 17, in which powder granulometry of both the active substance and N-vinyl-2-pyrrolidone/viny acetate copolymer is within a range between 0.01 and 1,000 microns.

32-33. (Cancelled)

34. (New) The method according to claim 17, in which the co-grinding step is carried out for times between 0.5 to 8 hours.